As filed with the Securities and Exchange Commission on July 16, 2021
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
Under
The Securities Act of 1933
TSCAN THERAPEUTICS, INC.
(Exact name of Registrant as specified in its charter)
| | |
Delaware | | 82-5282075 |
(State or other jurisdiction of incorporation or organization) | | (IRS Employer Identification No.) |
830 Winter Street
Waltham, Massachusetts 02451
(Address of Principal Executive Offices)
TScan Therapeutics, Inc. 2021 Equity Incentive Plan
TScan Therapeutics, Inc. 2021 Employee Stock Purchase Plan
TScan Therapeutics, Inc. 2018 Stock Plan
(Full title of Plan)
David Southwell
President and Chief Executive Officer
TScan Therapeutics, Inc.
830 Winter Street
Waltham, Massachusetts 02451
(Name and address of agent for service)
(857) 399-9500
(Telephone number, including area code, of agent for service)
Copies to:
|
Timothy H. Ehrlich Jeffrey R. Vetter Keith J. Scherer Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP One Marina Park Drive, Suite 900 Boston, MA 02210 (617) 648-9100 |
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| | | | | | |
Large accelerated filer | | ☐ | | Accelerated filer | | ☐ |
| | | |
Non-accelerated filer | | ☒ | | Smaller reporting company | | ☒ |
| | | |
| | | | Emerging growth company | | ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐